drugset / Trial / NCT03991741

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

NCT03991741

Phase 1 Terminated 3 enrolled Gregory Daniels Immunotherapy Foundation · collab
NaSingle-groupOpen-labelTreatment

Summary

To determine whether special tumor fighting cells that is taken from participants' tumors and grown in the laboratory and then given back to the participant will fight the participant's cancer when their immune system is suppressed from attacking these special tumor fighting cells.

Timeline

Start
2020-10-07
Primary completion
2023-01-26
Completion
2023-01-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous Tumor Infiltrating Lymphocytes Cell therapy
Background aldesleukin Protein / enzyme biologic 720000 iu/kg